Highlights Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Real-time Estimate Cboe BZX Other stock markets 03:54:51 2024-05-06 pm EDT			5-day change	1st Jan Change
5.82 ^USD	-5.67%		+21.25%	+30.50%

Apr. 18	Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ
Apr. 18	Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 18	DJ
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	Apr. 18	MT
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	Apr. 18	CI
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	Apr. 06	CI
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours	Mar. 11	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M	Mar. 11	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11	CI
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA	Feb. 19	CI
Ocular Therapeutix, Inc. Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of Axpaxli in Wet Amd	Feb. 13	CI
Ocular Therapeutix Shares Rise as US FDA Modifies Enrollment Criteria, Drug Dosage for Axitinib Pivotal Study	Jan. 25	MT
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of Axpaxli in Wet AMD	Jan. 25	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q3 Revenue $15.1M	Nov. 07	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023	Nov. 07	CI
Ocular Therapeutix to Start Patient Enrollment for Wet AMD Trial; Shares Gain	Nov. 01	MT
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD	Nov. 01	CI
AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery	23-10-31	CI
Ocular Therapeutix Initiates First Pivotal Trial for OTX-TKI in Wet AMD Treatment	23-10-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Highlights

Filters